Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
27/07/2026 13:09
BRIEF-Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer July 27 (Reuters) - Spero Therapeutics Inc SPRO.O:
SPERO THERAPEUTICS APPOINTS DEBRA JESKE ZACK, M.D., PH.D., AS CHIEF MEDICAL OFFICER
Source text: ID:nGNX9GWcft
Further company coverage: SPRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)